Stem cell therapy seems to be a simple idea, but in practice it is not always so simple. Regenerative medicine can take molecules and cells and fix problems in the body, but it is a sad truth that there have not been many regenerative medicine treatments as of yet. One of the earliest kinds of cell therapy was blood transfusion and then bone marrow transplants came along, which helped cancer patients. When a patient suffers from severe burns or scalds, it is possible to treat them with cell therapy that uses a person’s own cells to heal them. While this is true, regenerative medicine has still not become a mainstream tool.
Much progress is being made to heal common diseases and injuries through regenerative medicine, but despite the many successes it has had, many of its therapies are not being approved. Even with reports coming out that it has saved countless patients, the cost of many of the therapies are keeping it from being a mainstream tool. Dr. Cameron Clokie has commented on the fact that it is too bad that the costs are so high, because it is very likely that in the future the cost of regenerative medicine will come down making it an extremely valuable kind of medicine that more attention should be given to.
Cameron Clokie is a scientist, entrepreneur, and maxillofacial and oral surgeon who heads up Induce Biologics Inc. as its CEO. The company focuses its efforts on regenerative medicine and especially solving problems related to musculoskeletal reconstruction. As a writer, Dr. Clokie has published a spread of important papers related to the subjects of regenerative medicine and the rebuilding of bones.
Cameron Clokie has been working in clinical practice and academic dentistry for 30 years, and in 1998 he was given the title of Head of Oral and Maxillofacial Surgery at the University of Toronto. He was also promoted to Professor of Maxillofacial and Oral Surgery by the same Univeristy and remained so until 2017 when he retired from academia. As a businessman, Dr. Clokie has worked with businesses to turn some of his 25 patents and pending patents into real-world commercial applications.